(NU/1433-11) GlycoScore: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation

Prostate cancer is the most common cancer in men in the UK. It develops slowly and can go undetected for many years. It has been estimated that the annual economic burden of the disease in the UK exceeds £269 million. This cost is expected to increase due to the rising prevalence of the disease, attributed to an ageing population. Current diagnosis relies on a combination of prostate-specific antigen (PSA) testing (which has low specificity and no prognostic value), and tissue biopsies (which are expensive, can be painful and only provide a snapshot of the tumour). A major problem is the difficulty distinguishing indolent benign (benign prostate hyperplasia (BHP)) and aggressive tumours. Thi…

Read all of it on Contracts Finder →